ProstaScore
Prediction of Non-evolutive Localized Prostate Cancer
DevelopmentActive
Key Facts
Indication
Prediction of Non-evolutive Localized Prostate Cancer
Phase
Development
Status
Active
Company
About OncoDiag
OncoDiag is a private, French diagnostics company developing a portfolio of non-invasive tests targeting major cancers including bladder, prostate, and colorectal. The company's lead product, Urodiag®, is already CE-marked for bladder cancer surveillance, positioning it in the early revenue stage. With a management team possessing decades of experience in diagnostics and oncology, and supported by a key scientific advisory board, OncoDiag aims to address significant unmet needs in cancer screening and monitoring through liquid biopsy and tissue-based approaches.
View full company profile